The company plans to address the FDA's concerns and resubmit its application for the product, which aims to treat so-called "off episodes", which affects nearly all patients of Parkinson's, heightening symptoms such as tremors and difficulty in walking, as medication wears off.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment